India's top court orders stray dogs to be removed from New Delhi streets
That could be possible in the future after India's top court ordered authorities in New Delhi to start removing all stray dogs from the streets, and to sterilize and relocate them to shelters permanently.
In its order Monday, the Supreme Court directed the capital's civic bodies to immediately initiate the process of capturing 5,000 stray dogs from 'high-risk areas' for now and send them to shelters equipped with adequate staff and CCTV surveillance within six to eight weeks.
It is unclear how the court arrived at the figure of 5,000 stray dogs. Various estimates put the number of strays in New Delhi between 500,000 to one million.
While many of the dogs that roam New Delhi's streets are harmless, the court's order aims to control rising dog biting cases, including cases involving children. Some estimates, based on hospital records, suggest New Delhi sees nearly 2,000 dog bite incidents every day.
'The situation is extremely grim,' the court said in its order, adding that it was passed while 'keeping (the) larger public interest in mind.'
'Infants, young children should not at any cost fall prey to stray dogs,' it said.
The court also ordered authorities to create an animal helpline within a week so that all dog bite cases in the capital can be reported. It said any individual or organization that stops authorities from removing stray dogs from the streets will face 'strict' legal consequences, while adding the strays should not to be released back on streets, in residential areas or in public places.
Animal lovers and activists had earlier opposed the court taking up the case. On Monday, the court chided them too.
'All these animal activists … will they be able to bring back those who have fallen prey to rabies?,' the court asked.
Rabies through dog bites is caused by a virus that invades the central nervous system. If left untreated, it is almost always fatal.
Shortly after the court's order, a senior minister of the state legislature in Delhi said his government will begin the process of rounding up the strays. Cabinet Minister Kapil Mishra said the court's order is a step towards freeing New Delhi 'from the fear of rabies and stray animals.'
'Special attention will also be given to the comprehensive welfare of stray animals,' Mishra said in a post on X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ...
Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aethlon Medical Inc (NASDAQ:AEMD) has made significant progress in its Australian oncology trial, with the first cohort of patients completing treatment without any device deficiencies or serious adverse events. The company has received formal approval from India's CDSCO to initiate an oncology trial, although they have decided to focus resources on the Australian trial for strategic reasons. Aethlon Medical Inc (NASDAQ:AEMD) has significantly reduced operating expenses by approximately 32%, primarily through payroll savings and reduced legal and consulting fees. The company is actively exploring the use of its hemo purifier for broader applications, including long COVID, and has presented promising pre-clinical data at a symposium. Aethlon Medical Inc (NASDAQ:AEMD) benefits from a 43% cash tax rebate in Australia, which helps offset research costs and makes conducting trials there financially advantageous. Negative Points The decision to not proceed with the Indian trial may delay potential strategic partnerships or regulatory approvals, as the company focuses solely on the Australian trial. Despite cost reductions, Aethlon Medical Inc (NASDAQ:AEMD) will still need to raise additional funds to continue its clinical research, as it does not yet have approved products for sale. The company faces challenges in accelerating patient enrollment in its Australian trial, although efforts are being made to address this through additional sites and recruitment strategies. The efficacy of the hemo purifier in actual clinical settings remains to be proven, as pre-clinical results may not directly translate to patient outcomes. Aethlon Medical Inc (NASDAQ:AEMD) is still in the early stages of its clinical trials, and it may take time to gather sufficient data to inform dosing and treatment effects. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with AEMD. Q: Can you confirm if the primary endpoint of the Australian study is safety, and if the first cohort has shown no adverse events related to the hemo purifier treatment? A: Yes, the primary endpoint is safety. We have successfully passed the first cohort with no adverse events, and an independent data safety monitoring board has recommended moving forward to the second cohort. (Dr. Steven La Rosa, Chief Medical Officer) Q: The pre-clinical data showed a 98.5% removal of extracellular vesicles in a simulated treatment. Should we expect similar results in the clinical study with actual patients? A: Laboratory results often differ from clinical outcomes. The true test will be the reduction observed in actual patients, and we hope to have data from the first cohort soon. (Dr. Steven La Rosa, Chief Medical Officer) Q: With the decision not to proceed with the Indian trial, what does this mean for your cash needs and strategic focus? A: We will need to continue raising funds, ideally with strategic partners. The decision to halt the Indian trial was more about avoiding delays in approval processes rather than cost savings. (Jim Frakes, CEO and CFO) Q: Are there any advantages to conducting clinical research in Australia compared to India, especially regarding costs and incentives? A: Australia offers a significant tax rebate of about 43%, which is not available in India. This rebate can make conducting research in Australia more cost-effective despite lower hospital costs in India. (Jim Frakes, CEO and CFO) Q: What efforts are being made to accelerate patient enrollment in the Australian trial? A: We are actively working on several initiatives, including pre-screening logs, recruiting additional sites, and using clinical trial liaisons and social media campaigns to speed up enrollment. (Dr. Steven La Rosa, Chief Medical Officer) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
FDA warns this cookware could be leaching lead into your food
Cookware that is likely still on shelves could be leaching lead into your food, the Food and Drug Administration said in an Aug. 13 warning. The FDA became aware of the issue after testing pots made by an Indian manufacturer and finding that they were made with Hindalium/Hindolium or Indalium/Indolium, metal alloys that are made from aluminum, aluminum alloys and brass. These substances are common in some types of imported cookware, said the FDA, but are not used in the U.S. due to their tendency to leach lead into food cooked or stored within. There is no known level of lead exposure that is considered safe and some people are at even higher risk of adverse effects, warned the agency, including young children, people of child-bearing age and people who are breastfeeding. Here's what to know. Which cookware is included in the warning? The FDA identified the manufacturer, an Indian aluminum cookware company called Saraswati Strips Pvt. Ltd that sells products under the brand name Tiger White. However, it was unable to contact a distributor to initiate a recall, meaning the impacted products are not being pulled from shelves on a large scale. Impacted products are Kadais/Karahis, or deep pots used for simmering and frying, with brand name Tiger White. The FDA tested two specific items at a Mannan Supermarket in Jamaica, New York, labeled "Pure Aluminium Utensils Tiger White RTM No: 2608606 An ISO 9001:2015 Certified Co. Saraswati Strips Pvt. Ltd. India." However, the FDA warns that these are not the only potentially affected products and more could be added as the investigation continues. What to do if you have an impacted product Consumers should check their homes for any listed products or similar cookware and throw them away. They should not attempt to refurbish or repair the cookware. If you are concerned about possible lead exposure, the FDA advises contacting your health care provider. Retailers and distributors are responsible for ensuring the safety of cookware they sell, said the FDA, meaning those that may have the affected products on the market should use the FDA's lead leach testing protocol for cookware or another testing method. They are also encouraged to consult with the FDA on the updated safety and regulatory status of food-related products. Questions for the FDA related to this topic can be sent to premarkt@ What is the risk of lead exposure? The FDA does not allow the use of lead in products related to food, including components of cookware and other food contact surfaces. Lead is toxic to humans and can be ingested when a product like the cookware leaches it into items it comes into contact with. Even low levels of exposure are linked to serious health issues, including fatigue, headache, stomach pain, vomiting or neurologic changes, according to the FDA. Exposure is especially dangerous to developing fetuses and children, potentially causing learning difficulties, low IQ and behavioral changes. Even when they don't show obvious symptoms, babies and children can be permanently impacted by elevated levels of lead in their blood, especially due to their smaller size and metabolism. This article originally appeared on USA TODAY: FDA warns about pots that may be leaching lead into food Solve the daily Crossword
CNET
5 hours ago
- CNET
Ultrahuman Calls Ring Air the World's Most Accurate Ovulation-Tracking Smart Ring After New Acquisition
Ultrahuman has taken an algorithm designed for intravaginal fertility monitors and transformed it into a non-invasive, temperature-sensing feature that can track your cycle right from your finger. The wearable health tech company announced today that it acquired viO HealthTech, which created the OvuSense algorithm. Validated in 13 peer-reviewed clinical publications and backed by 15 years of clinical research, the algorithm draws on data from over 260,000 cycles collected with medical-grade sensors. It was previously used in class II intravaginal medical fertility monitors. Now, Ultrahuman has adapted that technology for wellness tracking to create its Cycle and Ovulation Pro PowerPlug for the Ring Air. In a press release, Ultrahuman said Cycle and Ovulation Pro delivers over 90% accuracy in confirming ovulation -- a level the company says makes the Air the "world's most accurate cycle-tracking smart ring." This data comes from equivalence testing that compared OvuSense and Ring AIR with a multi-hormone ovulation prediction method that tracks rises in luteinizing hormone and progesterone. Though other cycle trackers may report different ovulation confirmation rates -- for example, the Oura Ring claims 96.4% -- that data isn't directly comparable to OvuSense and Ring Air's testing due to differences in validation protocols, datasets and definitions of detection. Ultrahuman Most platforms that track menstrual cycles rely on a 28-day cycle, but Cycle and Ovulation Pro takes into consideration that 87% of people who menstruate have varying cycles due to conditions such as polycystic ovary syndrome, endometriosis, non-bleeding, thyroid disorders or irregular bleeding. "This collaboration benefits from 15 years of clinically proven women's health expertise and applies it to the world's lightest smart ring," said Mohit Kumar, Ultrahuman CEO, in the press release. "For the first time, best-in-class hardware, software and algorithms with a clinical background come together in one wellness device. Our mission is to give women cutting-edge tools to optimize their health, combining clinical technology with comfort and style to deliver the most accurate women's health tool available." Cycle and Ovulation Pro complements Ultrahuman Ring Air's existing free Cycle and Ovulation PowerPlug, which provides basic conception and cycle tracking. Using physiological patterns and temperature biomarkers passively captured by the smart ring, the Pro version can support fertility planning, offer a space for mood, symptom and behavior logging and use temperature data to suggest hidden patterns in a cycle. Known as Cycle Flags, these patterns may include early, late or absent ovulation, a short luteal phase and trends potentially linked to conditions such as PCOS or miscarriage risk. Ultrahuman While the OvuSense algorithm is FDA-cleared for intravaginal use, the adapted, non-invasive version for the Ultrahuman Ring Air was created for general wellness and isn't FDA-cleared. In other words, the Ring Air isn't a substitute for contraception or for professional medical diagnosis and treatment. For those, you should consult your health care provider. How much does Ultrahuman's Cycle and Ovulation Pro cost? Now available in the US, UK, EU, Australia and Canada, Cycle and Ovulation Pro is a premium PowerPlug in the Ultrahuman app that costs $3.99 per month or $39.99 per year. The current Cycle and Ovulation PowerPlug remains free.
